Nalbuphine prevent postoperative hypergesia after remifentanil anesthesia during laparoscopic cholecystectomy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800020209

Enrollment

Unknown

Registered

2018-12-20

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Hyperalgesia

Interventions

A1:Nalbuphine+Remifentanil 0.1µg/kg/min

A2:Nalbuphine+Remifentanil 0.4µg/kg/min

B1:Saline+Remifentanil 0.1µg/kg/min

B2:Saline+Remifentanil 0.4µg/kg/min

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing laparoscopic cholecystectomy, ASA I-II; 2. aged 18-65 years; 3. BMI (Body Mass Index) 18.5~30 kg/m2; 4. With normal communication and certain learning ability; 5. Having signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Serious respiratory or circulatory diseases: such as severe atherosclerosis of coronary artery, cardiac failure, myocardial infarction, respiratory failure; 2. Neurological diseases: such as severe cerebral hemorrhage or cerebral infarction , hemiplegia or aphasia; 3. Mental illness: such as schizophrenia or depression; 4. Long-term abuse of drugs: including chemotherapy drugs and analgesics; 5. Obvious liver or kidney dysfunction; 6. Pregnant and lactating women; 7. allergy to opioid.

Design outcomes

Primary

Measure	Time frame
VAS Score;Postperative shivering;	—

Secondary

Measure	Time frame
Extubation time;time of stay in PACU;Vital signs at scheduled time point;supplementary analgesic drugs;	—

Countries

China

Contacts

Public ContactJun Hu

TongLing People's Hospital

hujund@139.com+86 13955910091

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026